Diagnosis and treatment of malignant pheochromocytoma with 131I-meta-iodobenzylguanidine: a case report.
The case of a 67-year-old male patient with metastatic malignant pheochromocytoma is described to illustrate the significant improvement of the diagnosis and treatment of pheochromocytoma since the recent introduction of 131I-meta-iodobenzylguanidine (131I-MIBG). Because of the generally observed tumor heterogeneity as to 131I-MIBG uptake and radiosensitivity in advanced disease, treatment results may be improved further, if 131I-MIBG therapy is initiated when tumor load is still small.
Konings
J E
JE
The Netherlands Cancer Institute (Antoni van Leeuwenhoekhuis), Amsterdam.
Bruning
P F
PF
Abeling
N G
NG
van Gennip
A H
AH
Hoefnagel
C A
CA
D019797:3-Iodobenzylguanidine; D000368:Aged; D002395:Catecholamines / Q000652:urine; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007462:Iodobenzenes / Q000627:therapeutic use; D008297:Male; D009362:Neoplasm Metastasis; D010673:Pheochromocytoma / Q000000981:diagnostic imaging / Q000532:radiotherapy; D011877:Radionuclide Imaging; D013565:Sympatholytics / Q000627:therapeutic use
D002395:Catecholamines; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D013565:Sympatholytics; D019797:3-Iodobenzylguanidine